US equities
|
MU
$953.19
▼-3.62%
NVDA
$228.52
▲+0.97%
META
$762.50
▲+2.63%
AAPL
$341.27
▲+0.09%
MSFT
$543.45
▲+0.43%
SNDK
$1,482.33
▼-0.34%
AMD
$605.53
▲+1.90%
SPCX
$156.54
▼-4.21%
MU
$953.19
▼-3.62%
NVDA
$228.52
▲+0.97%
META
$762.50
▲+2.63%
AAPL
$341.27
▲+0.09%
MSFT
$543.45
▲+0.43%
SNDK
$1,482.33
▼-0.34%
AMD
$605.53
▲+1.90%
SPCX
$156.54
▼-4.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
TScan Therapeutics, Inc. - Common Stock
(NQ:
TCRX
)
0.2167
-0.0212 (-8.91%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about TScan Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
December 05, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
December 02, 2024
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
November 05, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
October 04, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences
August 29, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Updates to its Board of Directors
June 14, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
May 30, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
May 29, 2024
RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
May 09, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
April 24, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
April 22, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Closing of Upsized Public Offering
April 19, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
April 17, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
April 16, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
April 16, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
April 08, 2024
Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 06, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
February 26, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
February 14, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
February 06, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
January 29, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
January 18, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
January 04, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
December 09, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
